$36 Million

Ovid Therapeutics

Follow-on Offering

Lead Left Bookrunner, October 2019

Ovid Therapeutics
Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).